Cargando…
Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model
Amlodipine, a commonly prescribed anti-hypertensive drug, shows increased systemic exposure with cytochrome P450 (CYP) 3A inhibitors. Ritonavir (RTV) is a potent mechanism-based and reversible CYP3A inhibitor and moderate inducer that is used as a pharmacokinetic enhancer in several antiviral treatm...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer US
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953987/ https://www.ncbi.nlm.nih.gov/pubmed/29427135 http://dx.doi.org/10.1007/s10928-018-9574-0 |
_version_ | 1783323428508401664 |
---|---|
author | Mukherjee, Dwaipayan Zha, Jiuhong Menon, Rajeev M. Shebley, Mohamad |
author_facet | Mukherjee, Dwaipayan Zha, Jiuhong Menon, Rajeev M. Shebley, Mohamad |
author_sort | Mukherjee, Dwaipayan |
collection | PubMed |
description | Amlodipine, a commonly prescribed anti-hypertensive drug, shows increased systemic exposure with cytochrome P450 (CYP) 3A inhibitors. Ritonavir (RTV) is a potent mechanism-based and reversible CYP3A inhibitor and moderate inducer that is used as a pharmacokinetic enhancer in several antiviral treatment regimens. Drug–drug interaction (DDI) between RTV and amlodipine is due to mixed inhibition and induction of CYP3A4, which is challenging to predict without a mechanistic model that accounts for the complexity of both mechanisms occurring simultaneously. A novel physiologically-based pharmacokinetic (PBPK) model was developed for amlodipine, and the model was verified using published clinical PK and DDI data. The verified amlodipine PBPK model was linked to a pharmacodynamics model that describes changes in systolic blood pressure (SBP) during and after co-administration with RTV. The magnitude and time course of RTV effects on amlodipine plasma exposures and SBP were evaluated, to provide guidance on dose adjustment of amlodipine during and after co-administration with RTV-containing regimens. Model simulations suggested that the increase in amlodipine’s plasma exposure by RTV diminishes by approximately 80% within 5 days after the last dose of RTV. PBPK simulations suggested that resuming a full dose of amlodipine [5 mg once daily (QD)] immediately after RTV’s last dose would decrease daily average SBP by a maximum of 3.3 mmHg, while continuing with the reduced dose (2.5 mg QD) for 5 days after the last dose of RTV would increase daily average SBP by a maximum of 5.8 mmHg. Based on these results, either approach of resuming amlodipine’s full dose could be appropriate when combined with appropriate clinical monitoring. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10928-018-9574-0) contains supplementary material, which is available to authorized users. |
format | Online Article Text |
id | pubmed-5953987 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Springer US |
record_format | MEDLINE/PubMed |
spelling | pubmed-59539872018-05-18 Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model Mukherjee, Dwaipayan Zha, Jiuhong Menon, Rajeev M. Shebley, Mohamad J Pharmacokinet Pharmacodyn Original Paper Amlodipine, a commonly prescribed anti-hypertensive drug, shows increased systemic exposure with cytochrome P450 (CYP) 3A inhibitors. Ritonavir (RTV) is a potent mechanism-based and reversible CYP3A inhibitor and moderate inducer that is used as a pharmacokinetic enhancer in several antiviral treatment regimens. Drug–drug interaction (DDI) between RTV and amlodipine is due to mixed inhibition and induction of CYP3A4, which is challenging to predict without a mechanistic model that accounts for the complexity of both mechanisms occurring simultaneously. A novel physiologically-based pharmacokinetic (PBPK) model was developed for amlodipine, and the model was verified using published clinical PK and DDI data. The verified amlodipine PBPK model was linked to a pharmacodynamics model that describes changes in systolic blood pressure (SBP) during and after co-administration with RTV. The magnitude and time course of RTV effects on amlodipine plasma exposures and SBP were evaluated, to provide guidance on dose adjustment of amlodipine during and after co-administration with RTV-containing regimens. Model simulations suggested that the increase in amlodipine’s plasma exposure by RTV diminishes by approximately 80% within 5 days after the last dose of RTV. PBPK simulations suggested that resuming a full dose of amlodipine [5 mg once daily (QD)] immediately after RTV’s last dose would decrease daily average SBP by a maximum of 3.3 mmHg, while continuing with the reduced dose (2.5 mg QD) for 5 days after the last dose of RTV would increase daily average SBP by a maximum of 5.8 mmHg. Based on these results, either approach of resuming amlodipine’s full dose could be appropriate when combined with appropriate clinical monitoring. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1007/s10928-018-9574-0) contains supplementary material, which is available to authorized users. Springer US 2018-02-09 2018 /pmc/articles/PMC5953987/ /pubmed/29427135 http://dx.doi.org/10.1007/s10928-018-9574-0 Text en © The Author(s) 2018 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. |
spellingShingle | Original Paper Mukherjee, Dwaipayan Zha, Jiuhong Menon, Rajeev M. Shebley, Mohamad Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model |
title | Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model |
title_full | Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model |
title_fullStr | Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model |
title_full_unstemmed | Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model |
title_short | Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model |
title_sort | guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic model |
topic | Original Paper |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5953987/ https://www.ncbi.nlm.nih.gov/pubmed/29427135 http://dx.doi.org/10.1007/s10928-018-9574-0 |
work_keys_str_mv | AT mukherjeedwaipayan guidingdoseadjustmentofamlodipineaftercoadministrationwithritonavircontainingregimensusingaphysiologicallybasedpharmacokineticpharmacodynamicmodel AT zhajiuhong guidingdoseadjustmentofamlodipineaftercoadministrationwithritonavircontainingregimensusingaphysiologicallybasedpharmacokineticpharmacodynamicmodel AT menonrajeevm guidingdoseadjustmentofamlodipineaftercoadministrationwithritonavircontainingregimensusingaphysiologicallybasedpharmacokineticpharmacodynamicmodel AT shebleymohamad guidingdoseadjustmentofamlodipineaftercoadministrationwithritonavircontainingregimensusingaphysiologicallybasedpharmacokineticpharmacodynamicmodel |